MIK665-S-64315-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMIK665Cat.No.:HY-112218CASNo.:1799631-75-6Synonyms:S-64315分?式:C??H??ClFN?O?S分?量:875.41作?靶點(diǎn):Bcl-2Family作?通路:Apoptosis儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:≥125mg/mL(142.79mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.1423mL5.7116mL11.4232mL5mM0.2285mL1.1423mL2.2846mL10mM0.1142mL0.5712mL1.1423mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(2.38mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.08mg/mL(2.38mM);ClearsolutionBIOLOGICALACTIVITY?物活性MIK665(S-64315)，于S63845，?種髓系細(xì)胞??病序列1(MCL1)抑制劑，對MCL1的IC50為1.81nM[1]。IC50&TargetMcl-11.81nM(IC50)體外研究MIK665(S-64315)hassimilarsynergisticeffectsasS63845,whencombinedwithABT-199.ThecombinationS64315(0.156-10μM)andABT-199(625nM)hassimilarefficacyinreducingthecellviabilityofrepresentativemelanomalines(MB2141,MB3616,MB3961,MB4667,A375,and1205Lucells)[1].MIK665isextractedfrompatentWO2016207225A1,compoundPreparation13,andinhibitsH929cellwithanIC50of250nM[2].戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CancerLett.2022Nov30;216028.?CellDeathDis.2020Jun8;11(6):443.?JInvestDermatol.2021Dec20;S0022-202X(21)02617-8.?Cancers.2020Aug5;12(8):2182.?Pharmaceuticals.2021,14(8),749.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ZoltánSZLáVIK,etal.Newhydroxyesterderivatives,aprocessfortheirpreparationandpharmaceuticalcompositionscontainingthem.WO2016207225A1.[2].MukherjeeN,etal.SimultaneouslyInhibitingBCL2andMCL1IsaTherapeuticOptionforPatientswithAdvancedMelanoma.Cancers(Basel).2020;12(8):2182.Published2020Aug5.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchu